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Lovastatin is a cholesterol-lowering agent, which competitively inhibits the enzyme HMG-CoA
reductase. Several HPLC methods for its analysis have been developed but there is no report of
its determination using capillary electrophoresis (CE). In this paper, we report the development
of a simple CE method for lovastatin determination, which is selective with respect to its deg-
radation products and useful for routine analyses. Since the molecule of lovastatin in its lactone
form is uncharged and is only slightly soluble in water, base hydrolysis was used to open the lactone
ring and transform the compound into a water-soluble acid form, which is negatively charged. Dif-
ferent solvents, different amounts of NaOH added, different hydrolysis times and different tem-
peratures for sample preparation were tested. The CE and HPLC methods are compared in terms






• capillary electrophoresis, CE
• high performance liquid
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INTRODUCTION
Lovastatin, simvastatin, pravastatin and mevastatin are
structurally similar cholesterol-lowering agents called
statins. They competitively inhibit the enzyme HMG-CoA
(3-hydroxy-3-methylglutaryl-coenzyme A) reductase, a
rate-limiting enzyme, which catalyzes the conversion of
hydroxymethylglutarate to mevalonate, an early and rate
limiting step in the biosynthesis of cholesterol.1,2 Liver
is the main site of cholesterol synthesis in the body.1 The
drug is administered to patients as the prodrug lactone,
which is converted to its hydroxy acid form in vivo.1
Several HPLC methods for the analysis of lovastatin
have been developed3–6 but there is no report on the use
of capillary electrophoresis (CE).
The expiry time of many pharmaceutical products is
limited by the susceptibility of the drug substance to oxi-
dative degradation. The susceptibility of statins to oxida-
tive degradation is well established.7–10 Apart from the
loss of drug potency, other stability problems, such as
changes in the dissolution rate, discolouration, generation
of toxic degradation compounds of the final pharmaceu-
tical formulation, are also very common. To assure the
efficacy and safety of pharmaceutical products with drugs
susceptible to oxidative degradation, a precise method is
needed. Volative degradation products and degradation
products without chromophores are possible and there-
fore also monitoring of the main compound is recom-
mendable.
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In this paper, we report the development of a CE
method for lovastatin, which is selective towards its deg-
radation products. The CE and HPLC methods11 are




Lovastatin was obtained from Krka, d.d., Novo Mesto (Slo-
venia), and was at least 99 % pure. All solvents and reagents
were of analytical grade.
Oxidation Procedure
The sample was oxidized in a Perkin Elmer differential scan-
ning calorimeter (DSC), type DSC-7, equipped with water
cooling.
Experimental conditions: 50-l aluminium crucibles
with four holes, dry oxygen atmosphere with 40 ml/min flow
rate, isothermal heating at 135 °C for 15 minutes. Sample
masses were 2.0–2.4 mg. Oxidized samples were analyzed
by HPLC and CE.12
Determination of Lovastatin by CE
The sample from an aluminium crucible was transferred
quantitatively into a 5 ml Erlenmayer flask, dissolved in
200 l of methanol (Merck, HPLC grade), using an ultra-
sound bath if necessary (sample solution 1). 50 l of solu-
tion 1 was transferred into a 2-ml vial and 50 l of 0.1 M
NaOH (Riedel-deHaen, p.a.) was added. In order to com-
plete the hydrolysis of lovastatin lactone into hydoxy acid,
the vial was covered and left at room temperature for at least
30 minutes. After that, 250 l of water was added and the
CE analysis was performed.
For calibration purposes, a standard solution of lovasta-
tin was prepared at a concentration of about 10 mg ml–1 in
methanol (standard solution 1) and treated in the same way
as described for the oxidized sample solutions.
The CE analyses were performed on a Hewlett-Packard,
HP 3D CE apparatus (Walbronn, Germany) using the Chem-
Station software. The fused silica capillary was 64.5 cm long
(56 cm to the detector) with an internal diameter of 50 m
and with a bubble cell (150 m light path length). Separa-
tion buffer was prepared by mixing 65 ml of 0.2 M borate
buffer solution, pH = 9.3 (solution A) (Fluka Chemie AG,
p.a.) and 35 ml of 0.05 M borate buffer solution, pH = 9.3,
with 0.1 M sodium dodecyl sulphate, SDS (solution B)
(Hewlett-Packard, CE grade). The optimal separation para-
meters were: buffer, A,B = 65 : 35; injection, 40 mbar, 10 s;
voltage, 30 kV; temperature, 30 °C; detection, 238 nm (band
width 16 nm). The current was about 87 A and the migra-
tion time of lovastatin acid about 14 minutes. The migra-
tion times of oxidized products ranged from 5 to 14 min-
utes and from 15 to 16 minutes. The capillary was rinsed
for 3 minutes with running buffer before each run.
Determination of Lovastatin by HPLC
The sample from an aluminium crucible was transferred
quantitatively and dissolved in 2.0 ml of acetonitrile (J. T.
Baker, HPLC grade). Standard solutions used for calibration
purposes were prepared in the same way as described for
sample solutions.
Quantitative HPLC analyses according to The European
Pharmacopoeia11 were performed on a Hewlett-Packard 1100
VWD HPLC system using a Eurosphere C18 (endcapped
octadecylsilane) 250 mm, 4.6 mm i.d., column with 5 m
particles equilibrated at 25 °C. Acetonitrile (J. T. Baker, HPLC
grade) was used as mobile phase A, and mobile phase B
was aqueous 0.1 % H3PO4(aq) (Merck). The flow rate was
1.5 ml min–1, injection volume 5 l and peak detection was
at 238 nm. Analysis started with 60 % A and 40 % B for 5
minutes and then increased to 65 % B in 2 minutes. The
gradient was then ramped up to 90 % B in 5 minutes and
held there for the next 9 minutes. After 22 minutes (stop
time), the mobile phase B was decreased to 40 % and the
chromatographic system was equilibrated to the starting
condition for about 5 minutes.
Lovastatin eluted in approximately 10 minutes. The re-
tention times of oxidized products ranged from 2 to 16 min-
utes.
RESULTS AND DISCUSSION
The development of an alternative analytical method us-
ing CE to determine lovastatin and its oxidation products
after exposure to an oxidative atmosphere was based on
its chemical characteristics. The molecule of lovastatin
(Scheme 1) in lactone form, as it is administered to pa-
tients as a prodrug, does not have any charge and is only
slightly soluble in water (approx. 0.0044 mg ml–1).13
Base hydrolysis was used to open the lactone ring. The
compound was transformed to lovastatin acid and its
water solubility increased dramatically. Lovastatin acid
in its ionic form is negatively charged, which enables it
to be separated from other compounds in the sample.
Addition of the surfactant sodium dodecyl sulphate
(SDS) enables the neutral compounds in the sample so-
lution to partition between SDS micelles and buffer so-
lution based on their polar/nonpolar characteristics. It
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Scheme 1. Structures of lactone and hydroxy acid forms of lova-
statin.
enables the separation of the uncharged compounds
which result from the oxidation processes.
The shortest analysis time and the appropriate reso-
lution between lovastatin acid, impurities and oxidation
products were sought by selecting the appropriate elec-
trophoresis buffer and the optimal electrophoresis condi-
tions. At the same time, we attempted to narrow the
peak width of lovastatin acid, which would also contrib-
ute to better separation.
Selection of Optimal Electrophoretic Conditions
An electrophoresis buffer based on borate ions was cho-
sen in order to increase the selectivity by creating com-
plexes with hydroxyl groups of the sample molecules,
which were then drawn to the cathode.14
Buffer solutions with different ionic strengths were
tested and later modified by addition of different concen-
trations of SDS. The criteria for the optimal electrophore-
sis buffer were the migration time of lovastatin acid, and
the resolution between lovastatin acid and its oxidation
products, and between the oxidation products themselves.
Increasing the concentration of borate ions and de-
creasing the concentration of SDS in the buffer de-
creased the migration time, but unfortunately, decreased
the resolution as well (Figures 1 and 2).
The migration time of lovastatin acid decreased when
higher concentrations of borate buffer solution were used,
but a significant amount of heat was generated, even at
low voltages.
The optimal compromise chosen between these pa-
rameters was an electrophoresis buffer of the following
composition: 147 mmol dm–3 borate buffer solution and
35 mmol dm–3 SDS.
Further, we have proved that the migration time
could be decreased dramatically, without any significant
loss of resolution. For this purpose, the analyses were
modified by reversing the electrodes and injecting the
sample on the capillary side where the path to the detector
cell was shorter by aprox. 6.6 fold. Different concentra-
tions of borate buffer pH = 9.3 and different concentra-
tions of SDS were tested in this inverted configuration.
The migration time of lovastatin acid and the resolution
between its peak and the nearest neighbouring peaks were
followed. The migration time of lovastatin acid was
shortened, about 5.8 times on average (Figure 3), but the
resolution between individual peaks and lovastatin acid
was not suitable for quantitative evaluation.
On increasing the temperature, the migration time of
lovastatin acid decreased to about 20 minutes at 30 °C
and about 14 minutes at 35 °C. The temperature of 30 °C
was chosen as a compromise between suitable resolution
and migration time.
By shortening the injection time and/or decreasing
the pressure, using a hydrodynamic type of injection, the
injection volume of the sample was reduced, resulting in
lower sensitivity of the method. In the case of the chosen
hydrodynamic type of injection, with a pressure of 40
mbar and injection time of 10 s, the width of the
lovastatin acid peak at the baseline was about 0.7 min.
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Figure 1. Dependence of lovastatin acid migration time (tmigr.) on
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Figure 2. Dependence of migration time (tmigr.) of the five peaks
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Figure 3. Dependence of lovastatin acid migration time (tmigr.) on
the concentration of borate and SDS in inverted configuration.
Optimization of Sample Preparation
Influence of Solvent in Preparing the Lovastatin Solu-
tion. – We tried to prepare the lovastatin solution at con-
centrations of about 10 mg ml–1. Methanol and
acetonitrile were tested as solvents. Both solutions were
handled in the same manner (15 minutes in an ultra-
sound bath). Lovastatin dissolved completely in metha-
nol, but only partially in acetonitrile. No such difference
in solubility is reported in the literature.7
Influence of NaOH on Lovastatin Hydrolysis. – We ex-
pected that higher concentrations of lovastatin would re-
quire more NaOH for its hydrolysis. This implies also
higher ionic strength and undesired spreading of the
lovastatin acid peak. For hydrolysis of lovastatin to
lovastatin acid excess NaOH was added to the lovastatin
solution. At least 60 % (mole fractions) excess is needed to
complete the hydrolysis at room temperature within 30
minutes. With a decreased amount of NaOH (excess less
than 25 %), we observed that at a lovastatin concentration
higher than 5 mg ml–1 the hydrolysis was not complete. It
is seen as a plateau on the curve (Figure 4) where the data
are presented as detector response to the concentration of
lovastatin. Incomplete hydrolysis is also seen as the precip-
itate of non-hydrolyzed lovastatin after dilution with water.
Time Dependence of Lovastatin Hydrolysis. – The time
dependent course of lovastatin hydrolysis was followed
as the detector response. The results given in Table I
show that lovastatin hydrolysis (conc. 10 mg ml–1) was
complete within 30 minutes under the above described
experimental conditions.
Influence of Temperature on Lovastatin Hydrolysis. –
Lovastatin (conc. 10 mg ml–1) was hydrolyzed at room
temperature and at 37 °C. Temperature was found to have
no significant effect on the rate of hydrolysis (Table II), so
lovastatin hydrolysis was carried out at room temperature.
Comparison of CE and HPLC Methods
Selectivity Study. – The specificity and selectivity of the
chromatographic and electrophoretic methods was exam-
ined (Figure 5). For quantitative evaluation of non-oxi-
dized lovastatin in solutions exposed to oxygen, it is im-
portant to ensure separation of the lovastatin peak from
those of its oxidation products. In the »peak purity test«,
using a diode array detector, the UV spectra of different
parts of the peak do not differ significantly, indicating ho-
mogeneity of the lovastatin acid (CE) and lovastatin
(HPLC) peaks.
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Figure 5. Analysis of lovastatin solution exposed to an oxygen at-













regression line of the detector response up to the conc. 5 mg ml–1
detector response
Area = 0.494 + 0.073
 lovastatin / mg ml–1
C / (mg ml–1)
Figure 4. Dependence of detector response on the concentration
of the lovastatin starting preparation (solution 1) after the hydroly-
sis procedure. Lovastatin at concentrations > 5 mg ml–1 is not hy-
drolyzed because of an insufficient amount of NaOH. Detector re-
sponse measured as absorbance, A (A = log I0 / I; I0, incident
light intensity; I, transmitted light intensity).
TABLE I. Time dependence of lovastatin hydrolysis followed as de-
tector response
t / min Alovastatin acid








1440 (24h) 12.04013 101
average 12.06633 101
RSD 4.9 3.9
(a) Detector response measured as absorbance A.
(b) A30, A value after 30 min.
TABLE II. Temperature and time dependence of lovastatin hydroly-
sis process
Room temperature T = 37 C
t / min Alovastatin acid (A/c) / ml mg
–1 Alovastatin acid (A/c) / ml mg
–1
30 11.92131 0.6000 11.6482 0.5755
60 12.47367 0.6278 13.3338 0.6588
120 11.16885 0.5621 12.0051 0.5931
average 12.1721 0.5966 12.3290 0.6091
RSD 6.0 5.5 7.2 7.2
Quantitative Performance. – The quantitative aspects of
both methods were examined and the data are shown in
Table III.
Limits of Detection and Quantitation. – Limits of detec-
tion (LOD) and limits of quantitation (LOQ) were esti-
mated from the signal to noise ratios (S/N). In the limit
of detection (S/N = 3) and limit of quantitation (S/N =
10) tests, a series of diluted solutions of lovastatin was
prepared. The concentration of 0.025 g ml–1 and 0.10
g ml–1 for the HPLC method and 10.0 g ml–1 and 40.0
g ml–1 for the CE method were found to correspond to
LOD and LOQ, respectively.
Linearity. – The CE method is linear in the range from
LOD (10 g ml–1) to about 25 mg ml–1 of lovastatin
while the HPLC method is linear in the range from LOD
(0.025 mg ml–1) to about 1.2 mg ml–1 of lovastatin.
The correlation coefficients (peak area vs. sample
concentration) are shown in Table III. In both cases they
exceed 0.999, indicating good correlation. Detector re-
sponses at zero concentration, expressed in percents rel-
ative to the detector response at working concentration,
are acceptable in both cases (0.6 % for HPLC and
0.75 % for CE), but the working concentration using CE
is 10 times higher than for HPLC.
Precision. – The results of 6 successive injections of lo-
vastatin solution (HPLC, conc. = 1.0 mg ml–1) and lova-
statin acid solution show that the injection precision of
the HPLC method is, as expected, better (RSD = 0.1 %)
than that of CE (RSD = 1.1 %). We suppose that the rea-
son for the lower precision of CE is the type of injection,
which is hydrodynamic.
The repeatability of the method was determined by
the analysis of at least six sample solutions, prepared
from the same lovastatin sample. Due to the limited
amount of oxidized lovastatin available (in aluminium
crucibles about 5 mg substance can be oxidized at a
time, which is not enough for 6 sample solutions), the
repeatability of the method was performed on non-oxi-
dized lovastatin. The lovastatin assay was performed six
times using HPLC (RSD = 0.4 %) and eight times using
the CE method (RSD = 3.5 %). The CE determination of
lovastatin was based on the conversion of lovastatin into
lovastatin acid, which takes place irreversibly in alkaline
media in a relatively short time. In order to check the re-
peatability of the conversion of lovastatin into lovastatin
acid, a lovastatin solution was divided into six aliquots.
Each solution was hydrolyzed and analyzed using CE.
The RSD of six determinations of lovastatin acid was
3.2 %. These results confirmed that the repeatability of
lovastatin conversion into lovastatin acid in alkaline me-
dia was adequate.
These results show that the HPLC method for deter-
mining lovastatin is more precise and repeatable than the
CE method.
A comparison of HPLC and CE results of three
lovastatin samples after exposure to an oxygen atmo-
sphere (135 °C, 15 minutes) is shown in Table IV.
The difference between the CE and HPLC results is
relatively high, but considering the RSD value of the an-
alytical method repeatability (about 4 %) and the repeat-
ability of the oxidation processes,14 the difference is
within the expected limits.
The amount of lovastatin after exposing the sample
to an oxygen atmosphere decreased by about 40 %, but
the total content of impurities did not reach the level of
degraded lovastatin (Figure 5). We suppose that the volatile
oxidation products and the products without chromophores
(doubly bound in naphthalenediene ring) result from the
oxidation processes.
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TABLE III. Comparison of CE and HPLC methods in terms of regression parameters
Parameter of regression analysis HPLC CE
Lovastatin conc. range / mg ml–1 0.0002–1.2 0.02–25.0
Correlation coefficient, r2 0.9992 0.9993
Slope, a / ml mg–1 20.88740  0.23141 0.605039  0.011851
Intercept on y axis, b 0.12568  0.13181 0.046736  0.121017
Intercept on y axis, b / %(a) 0.60 0.75
Intercept on y axis, b / %(b) 0.60 6.7
(a) b is the intercept on y axis expressed in percents relative to the detector response at lovastatin concentrations of about 1.0 mg m–1 (HPLC) and
10.0 mg ml–1 (CE). These concentrations were chosen as working concentrations for calibration purposes.
(b) b is the intercept on y axis expressed in percents relative to the detector response at the lovastatin concentration of about 1.0 mg ml–1 (HPLC
and CE).
TABLE IV. Comparison of the results of HPLC and CE analytical
methods
Ser. no. Non-oxidized lovastation / %
HPLC CE HPLC-CE
1 70 66 4
2 78 70 8
3 60 56 4
CONCLUSION
The CE method developed in the present work is suit-
able for the routine analysis of lovastatin and its oxida-
tion products. It involves a simple transformation of the
lactone form of lovastatin into a hydroxy acid using base
hydrolysis. Comparison of the CE and HPLC methods
has shown that the latter is more precise, reproducible
and sensitive than the former, although the many advan-
tages of CE, such as small injection volume, simplicity
and wide applicability, should be taken into account.
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SA@ETAK
Usporedba metoda CE i HPLC pri odre|ivanju lovastatina i njegovih oksidativnih produkata
nakon izlaganja oksidiraju}oj atmosferi
Sandra Javernik Rajh, Samo Kreft, Borut [trukelj i Franc Vre~er
Lovastatin je spoj koji smanjuje nastajanje kolesterola, kompetitivno inhibiraju}i enzim HMG-Co-reduktazu.
Poznato je nekoliko HPLC-metoda za njegovu analizu, ali nema podataka o njegovom odre|ivanju kapilarnom
elektroforezom (CE). U ovom radu izvještavamo o razvoju jednostavne CE-metode za odre|ivanje lovastatina,
koja je selektivna prema njegovim degradacijskim produktima i uporabljiva u rutinskim analizama. Budu}i da
su lovastatin i njegov laktonski oblik nenabijeni i slabo topljivi u vodi, upotrebljena je lu`nata hidroliza za
otvaranje laktonskoga prstena i pretvaranje spoja u negativno nabijeni kiselinski oblik topljiv u vodi. Ispitana
su razli~ita otapala, dodatak razli~itih koli~ina NaOH, razli~ita vremena hidrolize i razli~ite temperature pripreme
uzoraka. Metode CE i HPLC su uspore|ene u smislu osjetljivosti, preciznosti, linearnosti i to~nosti. Ustanov-
ljeno je da je HPLC osjetljivija i preciznija metoda.
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